glp-1 for diabetes Receptor Agonists as Treatments Type 2 GLP-1 Drugs and Type 1
Description
[DOI] [PubMed] [Google Scholar] 46.He Y., Xu B., Zhang M., et al
Diabetes promotes the progression of MASLD to steatohepatitis, cirrhosis, and hepatocellular carcinoma
Bessette also said that more real-world evidence is needed to study the safety and effectiveness of GLP-1[s] and GLP-1/[gastric inhibitory polypeptides] in these underrepresented and previously excluded populations to guide treatment decisions.
Given the divergent outcomes of these studies, the efficacies of GLP-1R agonists for opioid-related responses need to be investigated in greater detail
